stockrowGlaukos Corporation
GKOS Healthcare Medical Devices
Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.
- Revenue
- +58.0%
- EPS
- +110.7%
- Free cash flow
- +411.2%
- Total debt
- −2.25%
Quarter to September 2026, against a year earlier
Follow GKOS
Alert me
Glaukos Corporation (GKOS) Revenue
Glaukos Corporation's revenue for fiscal 2025 was $507.4M, up 32.3% from $383.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was $690.3M. Over the past ten years it has ranged from $71.7M (fiscal 2015) to $507.4M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 3 consecutive fiscal years. Glaukos Corporation ranks 36th of 140 Medical Devices companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $507.4M | 32.33% |
| FY2024 | $383.5M | 21.85% |
| FY2023 | $314.7M | 11.26% |
| FY2022 | $282.9M | (3.79%) |
| FY2021 | $294.0M | 30.70% |
| FY2020 | $225.0M | (5.07%) |
| FY2019 | $237.0M | 30.73% |
| FY2018 | $181.3M | 13.83% |
| FY2017 | $159.3M | 39.21% |
| FY2016 | $114.4M | 59.55% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $211.0M | 13.70% |
| Jun 2026 | $185.6M | 23.27% |
| Mar 2026 | $150.6M | 5.21% |
| Dec 2025 | $143.1M | 7.18% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $10.5B |
| ZBH Zimmer Biomet Holdings, Inc. compare | $8.6B |
| BRKR Bruker Corporation compare | $3.5B |
| PODD Insulet Corporation compare | $3.2B |
| GMED Globus Medical, Inc. compare | $3.1B |
| BIO.B Bio-Rad Laboratories, Inc. compare | $2.6B |
| BIO Bio-Rad Laboratories, Inc. compare | $2.6B |
| PEN Penumbra, Inc. compare | $1.6B |
| GKOS Glaukos Corporation | $690.3M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on GKOS
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement